Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients

Avishay Grupper, Omar Abou Ezzeddine, Joseph Maleszewski, Ayelet Grupper, Jennifer R. Geske, Walter K Kremers, Sudhir S. Kushwaha, Naveen Luke Pereira

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Soluble ST2 (sST2) is a novel biomarker of inflammation and fibrosis. Elevated sST2 levels (≥35 ng/mL) are associated with worse outcomes in patients with heart failure (HF). There are sparse data regarding the significance of sST2 levels after heart transplantation (HTx). The study aims were to evaluate trends in soluble ST2 levels after the resolution of HF status with HTx and association between post-HTx sST2 levels and outcomes. Plasma sST2 levels were measured at baseline (median [IQR] of 118 days pre-HTx) and 12 months post-HTx in 62 subjects who were stratified into two groups by post-HTx sST2 levels < or ≥35 ng/mL: "Group 1" or "Group 2," respectively. Plasma sST2 levels were elevated in 58% of patients pre-HTx and in 50% of patients post-HTx. There was no association between elevated sST2 levels before and after HTx, and no significant differences in baseline characteristics between Group 1 and Group 2 patients. Group 2 as compared to Group 1 HTx recipients had significantly higher incidence of antibody-mediated rejection (AMR) for the entire post-transplant follow-up period (32% vs 4%, P = 0.006). There was no association between post-HTx sST2 level status and other post-HTx outcomes including survival. In conclusion, elevated plasma sST2 levels after HTx are associated with increased risk for AMR.

Original languageEnglish (US)
JournalClinical Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Antibodies
Heart Failure
Heart Transplantation
Fibrosis
Biomarkers
Inflammation
Transplants
Survival
Transplant Recipients
Incidence

Keywords

  • Antibody-mediated rejection
  • Heart transplant
  • ST2

ASJC Scopus subject areas

  • Transplantation

Cite this

Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients. / Grupper, Avishay; Abou Ezzeddine, Omar; Maleszewski, Joseph; Grupper, Ayelet; Geske, Jennifer R.; Kremers, Walter K; Kushwaha, Sudhir S.; Pereira, Naveen Luke.

In: Clinical Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

@article{d691c8a3616248029aa4bd98bc5fbac7,
title = "Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients",
abstract = "Soluble ST2 (sST2) is a novel biomarker of inflammation and fibrosis. Elevated sST2 levels (≥35 ng/mL) are associated with worse outcomes in patients with heart failure (HF). There are sparse data regarding the significance of sST2 levels after heart transplantation (HTx). The study aims were to evaluate trends in soluble ST2 levels after the resolution of HF status with HTx and association between post-HTx sST2 levels and outcomes. Plasma sST2 levels were measured at baseline (median [IQR] of 118 days pre-HTx) and 12 months post-HTx in 62 subjects who were stratified into two groups by post-HTx sST2 levels < or ≥35 ng/mL: {"}Group 1{"} or {"}Group 2,{"} respectively. Plasma sST2 levels were elevated in 58{\%} of patients pre-HTx and in 50{\%} of patients post-HTx. There was no association between elevated sST2 levels before and after HTx, and no significant differences in baseline characteristics between Group 1 and Group 2 patients. Group 2 as compared to Group 1 HTx recipients had significantly higher incidence of antibody-mediated rejection (AMR) for the entire post-transplant follow-up period (32{\%} vs 4{\%}, P = 0.006). There was no association between post-HTx sST2 level status and other post-HTx outcomes including survival. In conclusion, elevated plasma sST2 levels after HTx are associated with increased risk for AMR.",
keywords = "Antibody-mediated rejection, Heart transplant, ST2",
author = "Avishay Grupper and {Abou Ezzeddine}, Omar and Joseph Maleszewski and Ayelet Grupper and Geske, {Jennifer R.} and Kremers, {Walter K} and Kushwaha, {Sudhir S.} and Pereira, {Naveen Luke}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ctr.13349",
language = "English (US)",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients

AU - Grupper, Avishay

AU - Abou Ezzeddine, Omar

AU - Maleszewski, Joseph

AU - Grupper, Ayelet

AU - Geske, Jennifer R.

AU - Kremers, Walter K

AU - Kushwaha, Sudhir S.

AU - Pereira, Naveen Luke

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Soluble ST2 (sST2) is a novel biomarker of inflammation and fibrosis. Elevated sST2 levels (≥35 ng/mL) are associated with worse outcomes in patients with heart failure (HF). There are sparse data regarding the significance of sST2 levels after heart transplantation (HTx). The study aims were to evaluate trends in soluble ST2 levels after the resolution of HF status with HTx and association between post-HTx sST2 levels and outcomes. Plasma sST2 levels were measured at baseline (median [IQR] of 118 days pre-HTx) and 12 months post-HTx in 62 subjects who were stratified into two groups by post-HTx sST2 levels < or ≥35 ng/mL: "Group 1" or "Group 2," respectively. Plasma sST2 levels were elevated in 58% of patients pre-HTx and in 50% of patients post-HTx. There was no association between elevated sST2 levels before and after HTx, and no significant differences in baseline characteristics between Group 1 and Group 2 patients. Group 2 as compared to Group 1 HTx recipients had significantly higher incidence of antibody-mediated rejection (AMR) for the entire post-transplant follow-up period (32% vs 4%, P = 0.006). There was no association between post-HTx sST2 level status and other post-HTx outcomes including survival. In conclusion, elevated plasma sST2 levels after HTx are associated with increased risk for AMR.

AB - Soluble ST2 (sST2) is a novel biomarker of inflammation and fibrosis. Elevated sST2 levels (≥35 ng/mL) are associated with worse outcomes in patients with heart failure (HF). There are sparse data regarding the significance of sST2 levels after heart transplantation (HTx). The study aims were to evaluate trends in soluble ST2 levels after the resolution of HF status with HTx and association between post-HTx sST2 levels and outcomes. Plasma sST2 levels were measured at baseline (median [IQR] of 118 days pre-HTx) and 12 months post-HTx in 62 subjects who were stratified into two groups by post-HTx sST2 levels < or ≥35 ng/mL: "Group 1" or "Group 2," respectively. Plasma sST2 levels were elevated in 58% of patients pre-HTx and in 50% of patients post-HTx. There was no association between elevated sST2 levels before and after HTx, and no significant differences in baseline characteristics between Group 1 and Group 2 patients. Group 2 as compared to Group 1 HTx recipients had significantly higher incidence of antibody-mediated rejection (AMR) for the entire post-transplant follow-up period (32% vs 4%, P = 0.006). There was no association between post-HTx sST2 level status and other post-HTx outcomes including survival. In conclusion, elevated plasma sST2 levels after HTx are associated with increased risk for AMR.

KW - Antibody-mediated rejection

KW - Heart transplant

KW - ST2

UR - http://www.scopus.com/inward/record.url?scp=85051109936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051109936&partnerID=8YFLogxK

U2 - 10.1111/ctr.13349

DO - 10.1111/ctr.13349

M3 - Article

C2 - 29998506

AN - SCOPUS:85051109936

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

ER -